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Global burden of 
dementia 
As of 2013, there were an estimated 44.4 million 
people with dementia worldwide.  
 
This number will increase to an estimated 75.6 million 
in 2030, and 135.5 million in 2050.  
 
Much of the increase will be in developing countries.  
 
 
Source: http://www.alz.co.uk/research/files/WorldAlzheimerReport.pdf 
Already 62% of people with dementia live in developing 
countries, but by 2050 this will rise to 71%.  
 
Source: http://www.alz.co.uk/research/files/WorldAlzheimerReport.pdf 
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Alzheimer’s disease (AD) 
• Alzheimer’s disease is the most common form of dementia in the 
elderly, which accounts up to 80 % of all cases. 
 
• Clinical manifestation of the disease includes cognitive impairments 
such as attention deficit, spatial disorientation, speech disorders, 
and progressive loss of memory.  
 
• In the late stage of Alzheimer's, people generally lose the ability to 
communicate coherently, experience a decline in physical abilities 
and require total assistance with personal care.  
 
• Those with Alzheimer's live an average of eight years after their 
symptoms become noticeable to others, but survival can range from 
four to 20 years, depending on age and other health conditions. 
 
http://www.youtube.com/watch?v=2iHUXSVv8Mg 
 
 
•   
 
 • Late-onset (sporadic) Alzheimer's. This is the most common form of 
Alzheimer's disease, accounting for about 90% of cases, and usually 
occurs after age 65. It may or may not be hereditary.  
 
 The ApoE4 variant of gene encoding Apolipoprotein E (ApoE) is the 
largest known genetic risk factor for late-onset sporadic Alzheimer 
disease  
 
• Familial Alzheimer's disease (FAD) is a rare form of disease that is 
known to be entirely inherited. In affected families, members of at 
least two generations have had Alzheimer's disease. FAD is extremely 
rare, accounting for less than 1% of all cases of Alzheimer's disease. It 
has a much earlier onset (often in the 40s). 
 
 Early-onset Alzheimer's is linked with a genetic defects on chromosome 14 
(PSEN 1 gene), chromosome 1 (PSEN 2 gene), chromosome 21 (APP gene) 
to which late-onset Alzheimer's is not linked.  
 
 People with Down syndrome  (trisomy 21) are at risk for a form of early 
onset Alzheimer's disease as well. Adults with Down syndrome are often in 
their mid- to late 40s or early 50s when symptoms first appear. 
 
 
 
 
Pathophysiology of AD 
 
• AD is characterized by 
the accumulation of 
amyloid plaques and 
neurofibrillary tangles 
accompanied by 
impairment of the 
neurons in specific 
regions of the brain  
 
 
 
 
  
• Progressive atrophy of the frontal, 
parietal and temporal lobes is 
associated with loss of language 
and long-term memory, changes 
in personality and behavior. 
• The hippocampus and 
amygdala are among 
the first brain structures to 
be affected by 
Alzheimer’s disease which 
is correlated with 
emotional instability and 
short-term memory 
disturbance.  
 By the final stage, plaques and tangles spread throughout 
the brain, and brain tissue shrinks significantly 
 
• An increased deposition of amyloid-β 
peptide (Aβ), the main constituent of 
senile plagues, initiates a sequence 
of events that ultimately lead to AD 
dementia.  
 
• Aβ is derived from amyloidogenic 
cleavage of membrane bound 
amyloid precursor protein (APP) by β- 
and γ-secretase. 
 
•  Amyloidogenic processing of the 
APP leads to the production of Aβ 
peptides of different length 
 
• Aβ1-40 is the major species and the 
Aβ1-42 is the most fibrillogenic and 
predominant component in AD 
plaques. 
 
• Recent research has indicated that 
smaller Aβ aggregates, which are 
soluble in the intercellular fluid and 
may form at an earlier stage, are the 
most toxic form of the peptide. 
 
 
 
Amyloid Cascade Hypothesis 
• While Aβ is a key molecule in AD, epidemiological 
studies have shown that vascular disorders like 
atherosclerosis, ischemia, hypertension, stroke, transient 
ischemic attacks, microvessel pathology, and diabetes 
mellitus are among the risk factors for AD  
 
• In fact, cerebral hypoperfusion precedes cognitive 
decline, and neurodegeneration in AD.  
 
• Therefore, disturbance of cerebrovascular system is likely 
a major contributor to AD pathogenesis. 
 
Little is known about mechanisms that underlie Aβ induced 
damage of cerebrovascular cells.  
 
 
 
Blood-Brain Barrier Dysfunction in AD 
 
 
• Recent in vitro studies have demonstrated that 
amyloid-β peptide enhances adhesion and 
transmigration of monocytes across BBB.  
 
• Cell-cell adhesion is governed by the 
expression of adhesion molecules as well as 
the mechanical properties of the cells  
 
• However, the Aβ -enhanced adhesion 
between endothelial cells and monocytes has 
not been fully understood.   
 
• We aimed to study the direct effects of Aβ42 
oligomers on expressions of adhesion 
molecules and cell mechanical properties of 
CECs  
 ````````````````````````````` 
 • At least five steps of the 
adhesion cascade are 
capture, rolling, slow 
rolling, firm adhesion, 
and transmigration  
 
• Rolling adhesion is an 
initial step in 
transmigration of 
monocytes governed 
by dynamic bond 
formation and rupture 
between adhesion 
molecules selectins 
and their ligands. 
 
 
 http://www.youtube.com/watch?v=297HcgDxb7k 
Ligands for selectins: 
 
• P-selectin glycoprotein ligand 1 
(PSGL-1) 
• E-selectin ligand 1 (ESL-1) 
• Glycosylation-dependent cell 
adhesion molecule 1 (Gly-
CAM-1) 
• CD34 
 
Sialyl Lewis X (sLex). 
AFM cantilever tips bio-functionalized by sLex were 
applied to examine the sLex-selectin tethering at the 
cerebral endothelial cell surface  
Typical force curves obtained from AFM measurement. 
(A) Approach and retraction force curves with adhesion; and (B) 
without adhesion. The cantilever approaches (a to b), touches (b), 
makes indentation (b to c) and retracts (d) from the cell. Force of 
membrane tether formation (Fmtf) was measured at the sudden drop of 
force when a rupture of a membrane tether occurred (denoted by an 
arrow). 
Schematic descriptions of membrane tether formation 
and biofunctionalization for the AFM cantilever tip. 
Membrane tether formation mediated by sLex-selectin bonding during 
a monocyte rolling on the endothelial layer (upper) and the strategy 
using AFM cantilever tips bio-functionalized by sLex to characterize 
the mechanics of membrane tether adhesion (lower).  
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Aβ42 enhanced expression of  P- selectins on the cells 
surface and these effects were counteracted by lovastatin 
Effects of Aβ, histamine, and lovastatin on P-selectin 
expression at the CEC surface. (A) Fluorescent micrographs of 
fluorescently-labeled P-selectin at the bEnd3 cells. (B) Relative 
P-selectin intensity at the bEnd3 cell surface and (C) the human 
primary CEC surface.  
 
*** - p ≤ 0.001, ** - p ≤ 0.01 compared to the control; 
 ººº - p ≤ 0.001 compared to the 1 µM of Aβ. 
 
Aβ and histamine increase number of adhesion events for AFM 
cantilever tips bio-functionalized by sLex at the surface of the bEND3 
cells, while  lovastatin decreases adhesion probability  
 
Adhesion probability was calculated by normalizing the number of force curves 
with adhesion events by the total number of force curves. 
 
 ***p ≤ 0.001, **p ≤ 0.01 compared to the control;  
°°°0.001 compared to the Aβ (1 µM) treatment group.  
Adhesion  probability characterized by AFM 
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Aβ42 promoted actin polymerization within CECs and 
lovastatin decreased F-actin fluorescence  
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Effects of Aβ, and histamine on actin polymerization 
in CECs. (A) Fluorescent micrographs of Oregon-green 
phalloidinlabeled F-actin in bEnd3 cells. (B) Relative F-
actin intensity in bEnd3 cells 
and (C) primary human CECs. 
 
*** - p ≤ 0.001, ** - p ≤ 0.01, * - p ≤ 0.05 compared to the control;  
ººº - p ≤ 0.001 compare to the Aβ (1 µM) treatment. 
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AFM data showed that Aβ42 and histamine increased, and  
statin and latrunculin A decreased    
the overall cell stiffness. 
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The elastic modulus was calculated by fitting the cell indentation part of the 
force curves with Hertz model. 
 
*** - p ≤ 0.001, ** - p ≤ 0.01 compared to the control;  
ºº - p ≤ 0.01 compared to the Aβ (1 µM) treatment. 
  
Membrane stiffness is measured by 
calculating the slope (denoted by 
the arrow) from 5 nm indentation at 
the cell surface. 
 
***p ≤ 0.001, **p ≤ 0.01, *p ≤ 0.05 compared to the 
control;  
ºººp ≤ 0.001 compared to the Aβ (1 mM) treatment 
group. 
Aβ decreases membrane 
stiffness  
 
Fmtf was measured at the sudden drop of force when 
a rupture of a membrane tether occurred. 
 
***p ≤ 0.001, **p ≤ 0.01, *p ≤ 0.05 compared to the control;  
ººp ≤ 0.01 compare to the Aβ (1 mM) treatment group 
Aβ decreases membrane tether formation 
force (Fmtf) mediated by sLex-selectin 
bonding  
CECs 
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Aβ1-42 oligomers 
control NAC only 
A. 
Aβ42 30 min Aβ42 30 min + NAC 
Aβ42 induced ROS generation in bEnd3.  
Images of DHE-stained bEnd3 (A); relative DHE fluorescent 
intensity (B).  
 
** - p ≤ 0.01 compared to the control in each experimental group (unpaired T-test 
analysis) 
A. 
Aβ42 60 min 
control NAC only 
Aβ42 30 min Aβ42 30 min + NAC 
H₂O₂ 30 min 
Fluorescent images of anti-P-selectin labeled bEnd3 cells (A); 
relative P-selectin intensity in the mouse bEnd3 cells (B). 
 
*- p ≤ 0.05 compared to the control in each experimental group (unpaired T-test 
analysis) 
Aβ42 enhanced P-selectin fluorescence on the 
cell surface through elevated ROS 
A. 
control NAC only 
Aβ42 30 min Aβ42 30 min + NAC 
H2O2 30 min 
Fluorescent images of Oregon-green phalloidin-stained bEnd3 cells 
(A); relative F-actin intensity in mouse bEnd3 cells (B).  
 
* - p ≤ 0.05 compared to the control in each experimental group (unpaired T-test analysis).  
Aβ42 induced actin polymerization in mouse bEnd3 
cells through elevated ROS 
 
• Recent studies have indicated that the 
receptor for advanced glycation 
endproducts (RAGE) is a binding site for Aβ  
 
•  RAGE is a multiligand cell surface receptor 
which is normally expressed in brain 
endothelium and, at low levels, in microglia 
and neurons.   
 
• In AD brains RAGE expression is increased by 
several-fold in cerebral endothelial cells, 
astrocytes, microglia, and neurons. 
 
Both polyclonal antibody to 
RAGE and NADPH oxidase 
inhibitor significantly suppress 
oxidative stress induced by 
Aβ in CECs. 
 
 *- p≤0.05; ** - p ≤ 0.01; 
compared to the control;  
ºº - p ≤ 0.01 compared to the Aβ 
treatment 
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Images of dihydroethidium (DHE)-stained CECs 
treated with Aβ oligomers, polyclonal antibody to 
RAGE, ROS scavenger, and NADPH oxidase inhibitor  
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Polyclonal antibody to RAGE and NADPH oxidase 
inhibitor suppressed Aβ 1-42 induced colocalization 
of p47-phox to gp91-phox.  
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          NAC + Aβ42  AbRAGE + Aβ42  
Polyclonal antibody to RAGE suppressed oligomeric 
Aβ42 –induced upregulation of P-selectin at the bEnd3 
cell surface 
*** - p ≤ 0.001compared to the control;  
 ººº - p ≤ 0.001 compared to the Aβ treatment. 
total ERK1/2 
pERK1/2 
total-cPLA2α 
p-cPLA2α 
Polyclonal antibody to RAGE inhibits ERK1/2 and cPLA2α 
phosphorylation in CECs  
NADPH oxidase inhibitor and ROS scavenger inhibit ERK1/2 and 
cPLA2α phosphorylation in CECs 
Directly interact with 
plasma membrane ? 
Increase expression 
of adhesion 
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adhesion probability  
Increase permeability of 
BBB to  
 blood-born immune cells  
Decreases cell 
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Activate ERK1/2 
and cPLA2α 
 
Release of pro-inflammatory 
cytokines to attract blood-
born immune cells  
NEUROINFLAMMATION 
FUTURE RESEARCH DIRECTIONS  
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Neuro-inflammation 
 
Affected Aβ clearance 
(from brain)  
(ApoE4)  
Dysfunction of cerebrovascular system 
(ageing, oxidative stress, hypertension, 
hypercholesterolemia, diabetes etc.) 
Altered processes of Aβ 
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